SK Bioscience Wins More Funding for Vaccine Trials

SK Bioscience has secured some W200 billion in funding for coronavirus vaccine trials from the Coalition for Epidemic Preparedness Innovations, a global partnership (US$1=W1,127).

The funding is for third-phase trials of a COVID-19 vaccine currently under development. SK Bioscience said Monday the money will be used to test GBP510, a vaccine it is developing with the University of Washington.

CEPI already gave SK Bioscience funding for the first- and second-phase trials, bringing the total to US$210 million.

GBP510 is a "recombinant protein nanoparticle" vaccine, like Novavax, and SK plans to start production in the first half of next year.

CEPI was set up by the Wellcome Trust, Bill and Melinda Gates Foundation and the World Economic Forum. It gets its funding both from governments and individual donors.